Dr. Huang Zhenhua has been engaged in researching and developing innovative drugs for more than 20 years. He is the founder of KBP Biosciences Co., Ltd. developing drugs that uniquely meet unmet clinical needs.
Dr. Huang is a serial entrepreneur. He started his first venture in 1998. In 2002, he formed XuanZhu Pharma Co., Ltd. and sold it in 2012. Dr. Huang founded KBP Biosciences in 2011, dedicating himself to new molecular entity R&D. Under his leadership, KBP has built a strong pipeline for the global market, with multiple compounds in clinical development.
Dr. Huang obtained his PhD from Shenyang Pharmaceutical University, and EMBA from Peking University.
Benjamin Qiu is Partner of Healthcare Investment with Advantech Capital/New Horizon Capital.
Ben has 14 years of experience in healthcare investment, consulting and hospital management.
Since joining New Horizon in 2013, Ben has led deals covering a wide spectrum across healthcare space including pharmaceutical/biological innovative drugs (Zai Lab, Harbour BioMed，Synermore, KBP), medical services (Arrail Dental), medical devices (HealForce), precision medicine (Genetron Health) and mobile health (Wiwide Youkang).
Before joining New Horizon, Ben led deals of Kangning Hospitals Group (HKSE:2120) and Arrail Dental, as a key member of a healthcare dedicated private equity fund – GL Capital.
As one of the founding members of Healthcare Advisory team at PwC China, Ben built up a client base including big pharma companies and investment firms, providing strategy, operation improvement consulting and deal due diligence services.
Ben started his healthcare career by working with Vancouver General Hospital as an analyst/project leader.
Ben graduated from University of British Columbia with an MBA in Finance, and Eastern China University of Technology with a Bachelor Degree in Power Engineering. Ben also holds Chartered Finance Analyst and Certified Management Accountant designations.
Ms. Wan from SDICVC has over 10 years of experience in the healthcare industry and she has a deep understanding in all the sectors including new drugs, medical device and diagnosis, and medical service. Ms. Wan has in-depth experience in strategic planning, partnering, and mergers and acquisitions. Ms. Wan had four years of experience at Qiming Venture Partners, where she participated venture investment in Zai Lab, Berry Genomics, Canbridge and AmoyDx. Prior to that,Ms. Wan was a BD manager at Hutchison Medi Pharma (Shanghai) Ltd., a leading biopharmaceutical company in China. She participated in multiple clinical development projects, and contributed to the strategic collaborations between the Company and multinational pharmaceutical companies such as Eli Lilly and AstraZeneca.
Ms. Wan received a Bachelor of Pharmacy degree and a Master of Immunology Pharmacology degree from Wuhan University and Shanghai Institute of Materia Medica Chinese Academy of Sciences respectively. She holds her MBA degree from both China Europe International Business School and Duke University.
Fred Craves, PhD, is the Founder of Bay City Capital. Since launching the firm in 1997, Fred has built Bay City Capital to become one of the world’s premier life science investment firms investing in nearly 100 companies and raising more than $1.6 billion.
As a leader in healthcare venture capital, Dr. Craves brings both scientific skills and deep operational expertise to the companies in which he invests. This allows him to source outstanding investment opportunities and to support exceptional management teams in creating value. He has been associated with some of the most significant exits in the biopharmaceutical industry including Reliant Pharmaceuticals, a company he founded then sold to GlaxoSmithKline in 2007 in the single largest all-cash transaction for a venture backed biotech company at that time. He has served as Executive Vice President of Schering Berlin, Chief Executive Officer and President of Berlex Biosciences, Founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules.
Dr. Craves has been named to the Forbes Midas List, which recognizes the most successful investors in the venture capital asset class across both the technology and healthcare industries. He currently serves on the Boards of Dermira, Imidomics Inc., Madrigal Pharmaceuticals, Reset Therapeutics and Twist Bioscience. Previous investments and board participation, in addition to Reliant, include Medarex, Incyte Pharmaceuticals, and Ion Torrent. He earned a BS in Biology from Georgetown University and a PhD in Pharmacology and Toxicology from the University of California, San Francisco.
Mr. Spoor was previously President and CEO of AzurRx and was involved since the founding of the Company in June 2014. At AzurRx, he successfully led the company through its Phase 2 study in chronic pancreatitis and its Phase 2 OPTION study in cystic fibrosis. He previously was President, Chief Executive Officer and a member of the board of directors of Fluoropharma Medical, Inc., was the CFO for Sunstone BioSciences, a nanotechnology firm, and as a strategy consultant at Oliver Wyman working with biotechnology, pharmaceutical, medical device and health insurance companies. Mr. Spoor was an equity research analyst at J.P. Morgan and Credit Suisse covering the biotechnology and medical device industries. Prior to his career on Wall Street, Mr. Spoor worked in the pharmaceutical industry at Amersham /GE Healthcare where he worked in 7 countries in a variety of commercial and strategy roles. Mr. Spoor holds a Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting.